EU Regulators Lift Temporary COVID-19 Measures But Resources Remain An Issue
The European Medicines Agency said that while the temporary measures that were introduced to cope with the peak impact of the COVID-19 pandemic were no longer required, “resourcing within the entire European medicines regulatory network remains a challenge.”
You may also be interested in...
EMA To Restart Landmark Clinical Trial Transparency Policy In September
The European Medicines Agency is preparing to resume proactively publishing clinical trial data submitted by companies to support their marketing authorization applications for non-COVID-19 products.
EU CHMP Opinions And MAA Updates
This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.
EU Marketing Setback For Ipsen’s Connective Tissue Disease Drug
The European Medicines Agency is standing by its recommendation to reject Ipsen’s EU marketing authorization application for Sohonos, for treating fibrodysplasia ossificans progressiva.